New study aims to predict Chemo-Induced heart failure before it starts

NCT ID NCT05507879

Recruiting now Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study is for breast cancer patients receiving certain chemotherapies that can harm the heart. Researchers want to see if a genetic marker called TRPC6 can predict who will develop heart problems. By analyzing blood samples, they hope to find early warning signs and ways to protect heart health. The study involves 200 participants and is observational, meaning no new treatments are tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm cardiomyopathy congestive heart failure heart failure cardiomyopathy due to anthracyclines prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA CARDIOMYOPATHY CONGESTIVE HEART FAILURE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Florida
RECRUITING

Jacksonville, Florida, 32224-9980, United States

Contact Email: •••••@•••••
University of Florida
RECRUITING

Gainesville, Florida, 32610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.